Evaluating the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics.

Trial Profile

Evaluating the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Aprepitant (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Chemotherapy-induced nausea and vomiting; Early breast cancer
  • Focus Pharmacogenomic; Pharmacokinetics
  • Acronyms NRR
  • Most Recent Events

    • 12 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top